Medically reviewed by Doru Paul, MD Multiple myeloma is a type of blood cancer that develops in plasma cells, a type of white ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has previously been refractory to. Read more.

"Our relentless pursuit to provide each person diagnosed with blood cancer with treatment options at every stage of their disease ... New data highlight progress across all treatment stages of ...